Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Voyager Therapeutics, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing neurotherapeutics for central nervous system diseases. Its Form 8-K reports include quarterly and annual financial results, corporate updates, Regulation FD investor presentations, executive officer transitions and related exhibits covering pipeline and platform information.
Proxy materials describe annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification, charter matters and proposals involving authorized capital. The filing record also identifies Voyager’s common stock, par value and Nasdaq Global Select Market listing, and formalizes governance and capitalization disclosures relevant to its public-company status.
Voyager Therapeutics director George A. Scangos received a grant of stock options for 30,000 shares of common stock as director compensation. The options have an exercise price of $3.43 per share and expire on June 9, 2036.
According to the company’s 2025 Stock Incentive Plan, all 30,000 underlying shares vest upon the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, assuming he continues to serve as a director. After this grant, Scangos holds 30,000 stock options directly.
Voyager Therapeutics, Inc. director Catherine J. Mackey received a grant of stock options to acquire 30,000 shares of common stock. The options have an exercise price of $3.43 per share and expire on June 9, 2036.
According to the company’s 2025 Stock Incentive Plan and director compensation policy, all 30,000 underlying shares vest upon the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, as long as she continues serving as a director. Following this award, she holds 30,000 options directly from this grant.
Voyager Therapeutics, Inc. reported that director Steven Hyman received a grant of stock options to buy 30,000 shares of common stock at an exercise price of $3.43 per share. The award was made under the company’s 2025 Stock Incentive Plan as part of its director compensation policy.
All 30,000 underlying shares vest upon the earlier of one year from the grant date or the next annual meeting of stockholders, provided he continues to serve as a director. The filing does not show any option exercises or open-market share purchases or sales associated with this grant.
Voyager Therapeutics, Inc. director Nancy Vitale received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $3.43 per share and expire on June 9, 2036. All 30,000 underlying shares vest on the earlier of one year from the grant date or the next annual meeting of stockholders, subject to her continued service as a director. Following this grant, she holds options for 30,000 shares directly.
Voyager Therapeutics, Inc. director Michael J. Higgins received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of 3.43 per share and expire on June 9, 2036.
The award was issued under Voyager’s 2025 Stock Incentive Plan as part of its director compensation policy. All 30,000 underlying shares vest on the earlier of one year from the grant date or the next annual stockholder meeting, if he continues serving as a director.
Voyager Therapeutics director Jude Onyia received a grant of stock options covering 30,000 shares of common stock. The options have a $3.43 per share exercise price and expire on June 9, 2036, giving him the right to buy shares at that price in the future.
These options were issued under the company’s 2025 Stock Incentive Plan as part of its director compensation policy. All 30,000 underlying shares vest upon the earlier of one year from the grant date or the next annual stockholder meeting, subject to his continued board service.
Voyager Therapeutics director James A. Geraghty reported receiving a grant of stock options under the company’s 2025 Stock Incentive Plan. The award covers 30,000 options to buy common stock at an exercise price of $3.43 per share, expiring on June 9, 2036.
All 30,000 underlying shares vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided he continues serving as a director. After this grant, his reported derivative holdings from this award total 30,000 options.
Voyager Therapeutics director Grace Colon received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $3.43 per share and expire on June 9, 2036. They were granted under the company’s 2025 Stock Incentive Plan as part of its director compensation policy.
All 30,000 underlying shares vest upon the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, provided Colon continues to serve as a director through that date. This is a routine, compensation-related equity award rather than an open‑market stock purchase or sale.
Voyager Therapeutics director Glenn Pierce received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $3.43 per share and expire on June 9, 2036. All 30,000 underlying shares vest on the earlier of one year from the grant date or the next annual stockholders’ meeting, subject to his continued board service.
Voyager Therapeutics, Inc. reported results from its 2026 Annual Meeting of Stockholders and an amendment to its charter. Stockholders approved a Certificate of Amendment increasing authorized capital stock from 125,000,000 to 245,000,000 shares and authorized common stock from 120,000,000 to 240,000,000 shares. The additional common stock has the same rights as existing common shares, and the amendment became effective upon filing with the Delaware Secretary of State on June 9, 2026. Stockholders also elected directors and approved other meeting proposals based on the votes disclosed.